<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d45">
    <sentence id="DDI-DrugBank.d45.s0" text="Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.">
        <entity id="DDI-DrugBank.d45.s0.e0" charOffset="29-38"
            type="drug" text="etanercept"/>
        <entity id="DDI-DrugBank.d45.s0.e1" charOffset="74-81"
            type="drug" text="anakinra"/>
        <entity id="DDI-DrugBank.d45.s0.e2" charOffset="87-110"
            type="group" text="interleukin-1 antagonist"/>
        <ddi id="DDI-DrugBank.d45.s0.d0" e1="DDI-DrugBank.d45.s0.e0"
            e2="DDI-DrugBank.d45.s0.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s1" text="Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.">
        <entity id="DDI-DrugBank.d45.s1.e0" charOffset="6-25"
            type="group" text="TNFa-blocking agents"/>
        <entity id="DDI-DrugBank.d45.s1.e1" charOffset="38-45"
            type="brand" text="REMICADE"/>
        <entity id="DDI-DrugBank.d45.s1.e2" charOffset="73-80"
            type="drug" text="anakinra"/>
        <ddi id="DDI-DrugBank.d45.s1.d0" e1="DDI-DrugBank.d45.s1.e0"
            e2="DDI-DrugBank.d45.s1.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d45.s1.d1" e1="DDI-DrugBank.d45.s1.e1"
            e2="DDI-DrugBank.d45.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s2" text="Specific drug interaction studies, including interactions with MTX, have not been conducted.">
        <entity id="DDI-DrugBank.d45.s2.e0" charOffset="63-65"
            type="drug" text="MTX"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s3" text="The majority of patients in rheumatoid arthritis or Crohn s disease clinical studies received one or more concomitant medications."/>
    <sentence id="DDI-DrugBank.d45.s4" text="In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.">
        <entity id="DDI-DrugBank.d45.s4.e0" charOffset="57-59"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d45.s4.e1" charOffset="66-102"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d45.s4.e2" charOffset="105-114"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d45.s4.e3" charOffset="117-131"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s4.e4" charOffset="140-148"
            type="group" text="narcotics"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s5" text="Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.">
        <entity id="DDI-DrugBank.d45.s5.e0" charOffset="45-55"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d45.s5.e1" charOffset="58-67"
            type="group" text="antivirals"/>
        <entity id="DDI-DrugBank.d45.s5.e2" charOffset="70-84"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s5.e3" charOffset="87-90"
            type="drug" text="6-MP"/>
        <entity id="DDI-DrugBank.d45.s5.e4" charOffset="92-94"
            type="drug" text="AZA"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s6" text="In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.">
        <entity id="DDI-DrugBank.d45.s6.e0" charOffset="73-75"
            type="drug" text="MTX"/>
        <entity id="DDI-DrugBank.d45.s6.e1" charOffset="126-162"
            type="group" text="nonsteroidal anti-inflammatory agents"/>
        <entity id="DDI-DrugBank.d45.s6.e2" charOffset="165-174"
            type="drug" text="folic acid"/>
        <entity id="DDI-DrugBank.d45.s6.e3" charOffset="180-194"
            type="group" text="corticosteroids"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s7" text="Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.">
        <entity id="DDI-DrugBank.d45.s7.e0" charOffset="43-60"
            type="group" text="immunosuppressants"/>
        <entity id="DDI-DrugBank.d45.s7.e1" charOffset="135-152"
            type="group" text="immunosuppressants"/>
    </sentence>
    <sentence id="DDI-DrugBank.d45.s8" text="Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.">
        <entity id="DDI-DrugBank.d45.s8.e0" charOffset="6-15"
            type="drug" text="infliximab"/>
        <entity id="DDI-DrugBank.d45.s8.e1" charOffset="136-150"
            type="group" text="corticosteroids"/>
        <entity id="DDI-DrugBank.d45.s8.e2" charOffset="153-163"
            type="group" text="antibiotics"/>
        <entity id="DDI-DrugBank.d45.s8.e3" charOffset="166-178"
            type="drug" text="metronidazole"/>
        <entity id="DDI-DrugBank.d45.s8.e4" charOffset="183-195"
            type="drug" text="ciprofloxacin"/>
    </sentence>
</document>
